Phase II Study of Salvage Cellular Immunotherapy for Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation From an HLA-Matched Sibling Donor
- Assess the response rate of patients with recurrent multiple myeloma after an
allogeneic marrow transplant from a genotypically HLA identical sibling donor treated
with donor lymphocyte infusions as salvage therapy .
- Evaluate the safety and toxicity of this treatment when used as salvage therapy in
OUTLINE: Patients receive initial cell dose of donor lymphocytes (CD3+ cells) IV over 15-30
minutes. Patients with rapidly progressive disease may skip the initial cell dose and
proceed directly to dose escalation to receive CD3+ cells at a higher cell dose. Patients
who achieve complete response to the initial treatment may receive up to 2 additional
courses of escalating doses of CD3+ cells 8-12 weeks apart in the absence of unacceptable
toxicity. Patients are evaluated at 4 and 8 weeks after each infusion. Patients with disease
progression at 8 weeks are retreated at that time. Patients who achieve partial response or
stable disease at 8 weeks are re-evaluated at 12 weeks and may then be retreated.
Patients are followed every 2 weeks for 3 months, once a month for 9 months, and then every
2 months thereafter.
PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Neal Flomenberg, MD
Kimmel Cancer Center (KCC)
United States: Federal Government
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Medical College of Wisconsin Cancer Center||Milwaukee, Wisconsin 53226|